IV Lidocaine in Ortho Trauma Patients
The Efficacy of Perioperative Intravenous Lidocaine as an Opioid Sparing Adjunct for Patients Undergoing Lower Extremity Orthopedic Trauma Surgery
In this research study, we will be evaluating whether an anesthesia provider using the method of intravenous lidocaine infusion during the perioperative and immediate postoperative period can provide equal short-term pain control and decrease postoperative opioid consumption compared to traditional opioid utilization. We will also evaluate the effects of intravenous lidocaine on inflammatory mediators such as interleukins and cytokines through timed lab draws. The study hypothesis is that intravenous lidocaine will provide similar pain relief and decrease the amount of post operative opioids used, as well as decrease the amount of inflammatory mediators present compared to conventional post-operative treatment utilizing solely opioids.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Michigan
-
Detroit、Michigan、アメリカ、48201
- 募集
- Detroit Receiving Hospital
-
コンタクト:
- Jessica Phillips, PhD, CRNA
- 電話番号:313-577-9239
- メール:fy9015@wayne.edu
-
コンタクト:
- Mary Golinski, PhD, CRNA
- 電話番号:248 364 8776
- メール:golinski@oakland.edu
-
主任研究者:
- Jessica Phillips, PhD, CRNA
-
主任研究者:
- Mary Golinski, PhD, CRNA
-
主任研究者:
- Wael Saasouh, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- ASA physical status I-III, males and females >18 years of age and < 85 years of age, scheduled for repair of lower extremity (orthopedic) fracture/s of a single extremity. The type of injury will be documented and categorized- as applicable- in demographic data. The type of fracture will be extracted from the electronic surgical/operative report i.e. preoperative and postoperative diagnosis.
Exclusion Criteria:
- Contraindication to lidocaine including allergy, substantial hepatic impairment (alanine aminotransferase greater than 120 IU/L or aspartate aminotransferase > 80 IU/L), substantial renal impairment (serum creatinine >2 mg/dL), current history of narcotic abuse, cognitive impairment (any patients who are alert and oriented x2 or less; for example, 0-2), cardiac ejection fraction less than 20% by documented cardiac consultation and evaluation, history of seizure disorders, and patients with documented sensory impairments such as neuropathies, fibromyalgia, and diabetes mellitus with concomitant neuropathies (because these sensory impairments may confound postoperative measurements of pain). Cardiac Ejection Fraction less than 20% further explained: Patients who are admitted to the hospital and scheduled for surgery that are deemed high cardiac risk (by history and physical and/or per patient) routinely have echocardiograms per standard of care, and if necessary further cardiac consultations and 'work ups' are performed at Detroit Receiving Hospital. With the thorough history and physical that is required, the results will be available prior to surgery and anesthesia. If a patient has demonstrated 'no cardiac risk factors' after a complete history and physical examination, they will be assumed to have a normal ejection fraction. Pregnant women will also be excluded as there have been no controlled studies in humans investigating the potential effects of intravenous lidocaine during pregnancy. All patients undergo a serum or urine HCG test prior to surgery, and these will be evaluated by the researchers.
Patients under the age of 18 will be excluded due to recent studies finding adverse reactions, although mild, appear to be common in children. Oxygen saturation of <95% on room air will be excluded per the lidocaine package insert. Weight of 150 kg (330 lbs) will be excluded per the lidocaine package insert.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Control Group - Saline Infusion
Saline bolus and infusion |
Saline infusion |
|
実験的:Intervention - IV Lidocaine Group
Lidocaine bolus and infusion |
A Lidocaine (LID) bolus 2mg/kg followed by an infusion rate of 2 mg/kg/hr. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Morphine equivalents
時間枠:from enrollment to 14 days postoperative
|
Amount of opioids in morphine milligram equivalents (MME) used in 2 weeks/14 days postoperative period |
from enrollment to 14 days postoperative
|
|
Interleukin 6 (IL-6)
時間枠:1, 6, 24 and 48 hours postoperative
|
Interleukin 6 (IL-6) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Interleukin 8 (IL-8)
時間枠:1, 6, 24 and 48 hours postoperative
|
Interleukin 8 (IL-8) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Complement C3a
時間枠:1, 6, 24 and 48 hours postoperative
|
Complement C3a present in serum plasma at 1, 6, 24 and 48 hours postoperative in ng/mL |
1, 6, 24 and 48 hours postoperative
|
|
Visual Analogue Pain Score
時間枠:Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
Visual Analogue Pain Score with 0 = no pain and 10 = worst pain ever. |
Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quantitative Sensory Testing
時間枠:Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
Mechanical and thermal pain thresholds will be measured adjacent to the incision site to measure hyperalgesia |
Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- IRB 24-11-7305
- 2025-G-5 (その他の助成金/資金番号:AANA Foundation)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Any information containing patient information or protected health information (PHI) such as master list documents containing patient names and medical record numbers will be stored securely in a locked office inside a locked filing cabinet at the DMC site. All other data will use a subject number assigned and remove all 18 types of PHI information De-identified and be hard copies (paper records) will also be stored securely in a locked office inside a locked filing cabinet. DMC collected data will be saved on the DMC secure server in the Citrix platform. Study data will only be accessible to investigators involved in the study. Statistical analysis will be performed on de-identified encrypted digital data.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。